Decoupled syndecan 1 mRNA and protein expression is differentially regulated by angiotensin II in macrophages

Journal of Cellular Physiology

Volumn 214, Issue 3, 2008, Pages 750-756

  Wang, Wenli ^a   Haller, Carolyn A ^a   Wen, Jing ^a   Wang, Peiyi ^a   Chaikof, Elliot L ^a,b  

^a EMORY UNIVERSITY   (United States)

^b Georgia Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN I; APOLIPOPROTEIN E; CYCLIC AMP; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; STRESS ACTIVATED PROTEIN KINASE; SYNDECAN 1; ANGIOTENSIN II; BUCLADESINE;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; CELL SURFACE; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TISSUE REPAIR; ANIMAL; AORTA; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TIME; UPREGULATION;

MURINAE; MUS;

ANGIOTENSIN II; ANIMALS; AORTA; ATHEROSCLEROSIS; BUCLADESINE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; RNA, MESSENGER; SIGNAL TRANSDUCTION; SYNDECAN-1; TIME FACTORS; UP-REGULATION;

EID: 38449105958     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21271     Document Type: Article

References (46)

1. Alderman MH. 1996. Is there a link between the circulating renin-angiotensin system and coronary disease? A buoyant view. Heart 76:18-22.
2. Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. 1997. Plasma renin activity: A risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 10:1-8.
3. Bansal R, Kumar M, Murray K, Pfeiffer SE. 1996. Developmental and FGF-2-mediated regulation of syndecans (1-4) and glypican in oligodendrocytes. Mol Cell Neurosci 7:276-288.
4. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. 1999. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:729-777.
5. Brule S, Charnaux N, Sutton A, Ledoux D, Chaigneau T, Saffar L, Gattegno L. 2006. The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology 16:488-501.
6. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. 1998. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 83:952-959.
7. Cizmeci-Smith G, Langan E, Youkey J, Showalter LJ, Carey DJ. 1997. Syndecan-4 is a primary-response gene induced by basic fibroblast growth factor and arterial injury in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17:172-180.
8. Edwards IJ, Xu H, Obunike JC, Goldberg IJ, Wagner WD. 1995. Differentiated macrophages synthesize a heparan sulfate proteoglycan and an oversulfated chondroitin sulfate proteoglycan that bind lipoprotein lipase. Arterioscler Thromb Vasc Biol 15:400-409.
9. Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M. 2000. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 148:811-824.
10. Griendling KK, Alexander RW. 1997. Oxidative stress and cardiovascular disease. Circulation 96:3264-3265.
11. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. 1994. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74:1141-1148.
12. Griendling KK, Ushio-Fukai M, Lassegue B, Alexander RW. 1997. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 29:366-373.
13. Jaakkola P, Vihinen T, Maatta A, Jalkanen M. 1997. Activation of an enhancer on the syndecan-1 gene is restricted to fibroblast growth factor family members in mesenchymal cells. Mol Cell Biol 17:3210-3219.
14. Kaplan M, Aviram M, Knopf C, Keidar S. 2002. Angiotensin II reduces macrophage cholesterol efflux: A role for the AT-1 receptor but not for the ABC1 transporter. Biochem Biophys Res Commun 290:1529-1534.
15. Keidar S, Attias J, Heinrich R, Coleman R, Aviram M. 1999. Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis. Atherosclerosis 146:249-257.
16. Keidar S, Attias J, Smith J, Breslow JL, Hayek T. 1997. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 236:622-625.
17. Keidar S, Heinrich R, Kaplan M, Hayek T, Aviram M. 2001. Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized ldl: A possible role for interleukin-6. Arterioscler Thromb Vasc Biol 21:1464-1469.
18. Keidar S, Kaplan M, Hoffman A, Aviram M. 1995. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis 115:201-215.
19. Kim CW, Goldberger OA, Gallo RL, Bernfield M. 1994. Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns. Mol Biol Cell 5:797-805.
20. Kowala MC, Grove RI, Aberg G. 1994. Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis 108:61-72.
21. Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kubler W. 1999. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 19:1623-1629.
22. Lam JK, Matsubara S, Mihara K, Zheng XL, Mooradian AD, Wong NC. 2003. Insulin induction of apolipoprotein AI, role of SpI. Biochemistry 42:2680-2690.
23. Li L, Chaikof EL. 2002. Mechanical stress regulates syndecan-4 expression and redistribution in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 22:61-68.
24. Li L, Couse TL, Deleon H, Xu CP, Wilcox JN, Chaikof EL. 2002. Regulation of syndecan-4 expression with mechanical stress during the development of angioplasty-induced intimal thickening. J Vasc Surg 36:361-370.
25. Makaritsis KP, Gavras H, Du Y, Chobanian AV, Brecher P. 1998. AlphaI-adrenergic plus angiotensin receptor blockade reduces atherosclerosis in apolipoprotein E-deficient mice. Hypertension 32:1044-1048.
26. Meade TW, Cooper JA, Peart WS. 1993. Plasma renin activity and ischemic heart disease. N Engl J Med 329:616-619.
27. Mehta PK, Griendling KK. 2007. Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292:C82-C97.
28. Nikkari ST, Jarvelainen HT, Wight TN, Ferguson M, Clowes AW. 1994. Smooth muscle cell expression of extracellular matrix genes after arterial injury. Am J Pathol 144:1348-1356.
29. Ornskov D, Nexo E, Sorensen BS. 2007. Insulin induces a transcriptional activation of epiregulin, HB-EGF and amphiregulin, by a PI3K-dependent mechanism: Identification of a specific insulin-responsive promoter element. Biochem Biophys Res Commun 354:885-891.
30. Park PW, Reizes O, Bernfield M. 2000. Cell surface heparan sulfate proteoglycans: Selective regulators of ligand-receptor encounters. J Biol Chem 275:29923-29926.
31. Scheidegger KJ, Butler S, Witztum JL. 1997. Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J Biol Chem 272:21609-21615.
32. Schuh JR, Blehm DJ, Frierdich GE, McMahon EG, Blaine EH. 1993. Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 91:1453-1458.
33. Seo T, St Clair RW. 1997. Heparan sulfate proteoglycans mediate internalization and degradation of beta-VLDL and promote cholesterol accumulation by pigeon macrophages. J Lipid Res 38:765-779.
34. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. 2002. Angiotensin II stimulation of NAD(P)H oxidase activity: Upstream mediators. Circ Res 91:406-413.
35. Simon G, Abraham G. 1995. Angiotensin II administration as an experimental model of hypertension. In: Laragh JH, Brenner BM, editors. Hypertension: Pathophysiology, diagnosis, and management 2nd edition. New York: Raven Press Ltd. pp 1423-1435.
36. Smyth DC, Kerr C, Richards CD. 2006. Oncostatin M-induced IL-6 expression in murine fibroblasts requires the activation of protein kinase Cdelta. J Immunol 177:8740-8747.
37. Subramanian SV, Fitzgerald ML, Bernfield M. 1997. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem 272:14713-14720.
38. Wang W, Campos AH, Prince CZ, Mou Y, Pollman MJ. 2002a. Coordinate Notch3-hairy-related transcription factor pathway regulation in response to arterial injury. Mediator role of platelet-derived growth factor and ERK. J Biol Chem 277:23165-23171.
39. Wang W, Prince CZ, Mou Y, Pollman MJ. 2002b. Notch3 signaling in vascular smooth muscle cells induces c-FLIP expression via ERK/MAPK activation. Resistance to Fas ligand-induced apoptosis. J Biol Chem 277:21723-21729.
40. Weiss D, Kools JJ, Taylor WR. 2001a. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 103:448-454.
41. Weiss D, Sorescu D, Taylor WR. 2001b. Angiotensin II and atherosclerosis. Am J Cardiol 87:25C-32C.
42. Worapamorn W, Haase HR, Li H, Bartold PM. 2001. Growth factors and cytokines modulate gene expression of cell-surface proteoglycans in human periodontal ligament cells. J Cell Physiol 186:448-456.
43. Yeaman C, Rapraeger AC. 1993a. Membrane-anchored proteoglycans of mouse macrophages: P388DI cells express a syndecan-4-like heparan sulfate proteoglycan and a distinct chondroitin sulfate form. J Cell Physiol 157:413-425.
44. Yeaman C, Rapraeger AC. 1993b. Post-transcriptional regulation of syndecan-1 expression by cAMP in peritoneal macrophages. J Cell Biol 122:941-950.
45. Yu WH, Woessner JF Jr. 2000. Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7). J Biol Chem 275:4183-4191.
46. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 342:145-153.